Search
Plus Therapeutics Inc
PSTVAdd to Watchlist
3.870USD
0.0000.00%
Close 07-31 16:00（ET）
24.21MMarket Cap
LossP/E TTM
Plus Therapeutics Inc (PSTV) Stock Price Target & Forecast
Analyst Rating
Based on 4 analysts giving stock ratings to Plus Therapeutics Inc in the past month.
Buy
0 Strong Buy
4 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
32.500USD+1500.99%
PSTV Analyst Recommendation Trends
In the current month, PSTV has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PSTV average Analyst price target in the last month is 32.500.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
4
4
4
4
4
4
5
4
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
4
4
4
5
5
5
4
PSTV Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, PSTV EPS is projected to reach -0.910 in FY2026Q3, following reported EPS of -1.305 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.81
-0.88
-0.91
-0.91
-0.77
Actual
-1.04
-26.13
-1.31
--
--
Surprise
-27.66%
-2869.12%
-43.45%
--
--
FAQs
What is Plus Therapeutics Inc's expected revenue for the next quarter?
Plus Therapeutics Inc's expected revenue is 1.34M.
What is Plus Therapeutics Inc's price target?
Analysts forecast that Plus Therapeutics Inc's price target is USD 4.00, with the highest forecast at USD 21.00 and the lowest forecast at USD 2.00.
How have Plus Therapeutics IncPSTV's recent earnings per share performed?
The market expectation was USD -1.31, while Plus Therapeutics IncPSTV's earnings per share (EPS) for the previous quarter was USD -26.13. EPS for the next quarter is expected at USD -0.91.
What is the analyst rating for Plus Therapeutics Inc?
Based on the ratings of Plus Therapeutics Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.